Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jul:96:615-617.
doi: 10.1016/j.ijid.2020.05.115. Epub 2020 Jun 2.

Potential role of statins in COVID-19

Ken Cheah Hooi Lee  1 , Duu Wen Sewa  2 , Ghee Chee Phua  2
Affiliations
Review

Potential role of statins in COVID-19

Ken Cheah Hooi Lee et al. Int J Infect Dis. 2020 Jul.

Abstract

Patients with COVID-19 infection have an increased risk of cardiovascular complications and thrombotic events. Statins are known for their pleiotropic anti-inflammatory, antithrombotic and immunomodulatory effects. They may have a potential role as adjunctive therapy to mitigate endothelial dysfunction and dysregulated inflammation in patients with COVID-19 infection.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

    1. Albert M.A. PRINCE Investigators. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA. 2001;286(1):64–70. doi: 10.1001/jama.286.1.64. - DOI - PubMed
    1. Arsian F., Pasterkamp G., de Kleijn D.P. Unraveling pleiotropic effects of statins: bit by bit, a slow case with perspective. Circ Res. 2008;103(4):334–336. doi: 10.1161/CIRCRESAHA.108.182220. - DOI - PubMed
    1. Biere-Rafi S. Statin treatment and the risk of recurrent pulmonary embolism. Eur Heart J. 2013;34(24):1800–1806. doi: 10.1093/eurheartj/eht046. - DOI - PubMed
    1. Bozkurt B., Kovacs R., Harrington B. 2020. HFSA/ACC/AHA statement addresses concerns re: using RAAS antagonists in COVID-19.https://www.acc.org/latest-in-cardiology/articles/2020/03/17/08/59/hfsa-... - PMC - PubMed
    1. Chansrichavala P. Atorvastatin attenuates TLR4-mediated NF-kappaB activation in a MyD88-dependent pathway. Asian Pac J Allergy. 2009;27:49–57. - PubMed

Substances